In July 2017 the Company received an award in the amount of $15,912 from CIRM to aid in funding the Company’s Phase 3 study of NurOwn®, for the treatment of ALS. An aggregate amount of $9,050 and $7,050 related to the project was received through June 30, 2018 and December 31, 2017, respectively. The award does not bear a royalty payment commitment nor is the award otherwise refundable. $2,740 and $4,425 was recorded as participation by CIRM in research and development expenses during the 6 month ended in June 30, 2018 and during the year ended December 31, 2017, respectively.